Ovum, an Australian women's health data startup, has closed a $4 million seed round led by Admiralty Capital Group to expand its AI-driven health journal app and support longitudinal research focused on female health outcomes.
- Raised $4 million seed round led by Admiralty Capital Group
- App captures over 57,000 health data points from 20,000+ downloads
- Clinical trials underway with leading Australian hospitals
What happened
Ovum, an Australian startup focused on women’s health data, has secured $4 million in a seed funding round. The round was led by Admiralty Capital Group and included participation from Antler, Giant Leap, Aviron Investments, and other angel investors along with existing backer LaunchVic via the Alice Anderson Fund. Since its launch in August 2025 following a $1.7 million pre-seed raise, Ovum has grown rapidly, capturing extensive women’s health data through its AI-powered health journal app.
The app collects detailed information including symptoms, lifestyle choices, biometric data, and medical records, spanning all stages of reproductive health. This data is processed to identify health patterns and facilitate more informed conversations with healthcare providers. Ovum’s AI has supported over 107,000 user interactions, underscoring strong adoption among a diverse user base aged 15 to 84.
Why it matters
Ovum addresses a significant gap in women’s healthcare, which has historically lacked sufficient data and research tailored to female health experiences. Founder Dr Ariella Heffernan-Marks, motivated by her own challenges with misdiagnosed chronic migraines as a medical student, designed Ovum to empower women to better understand their bodies and advocate confidently in clinical settings.
The startup’s technology combines clinical research and AI to generate actionable insights, helping to improve healthcare equity and outcomes. Partnerships with organisations like Medibank, Fernwood Fitness, and the Australian Red Cross demonstrate Ovum's integration into the broader health ecosystem, while pilots and clinical trials at major hospitals aim to validate AI as a preventative health tool for women.
What to watch next
Ovum is set to use this new capital to enhance its AI capabilities and expand its longitudinal data collection, deepening its insights into women’s health trends over time. The company’s ongoing clinical trials at St George Hospital and the Royal Hospital for Women will be critical in demonstrating the potential of AI-driven tools to improve women’s health confidence, self-advocacy, and continuity of care.
Investor confidence highlights Ovum’s potential for wider impact, with Admiralty Capital noting the startup’s mission, timing, and strong leadership as key assets for growth. The startup’s progress will be closely watched as it aims to scale its user base and influence clinical standards in women’s healthcare both in Australia and potentially globally.